Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

42.64 +1.40 (+3.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Supernus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Clover Health, Surgery Partners, Illumina, Bruker, and Supernus Pharmaceuticals Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Economy
SUPN Q2 Deep Dive: Growth Drivers Shift to New Portfolio as Legacy Products Fade
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q2 CY2025 results topping the market’s revenue expectations, but sales fell by 1.7% year on year to $165.5 million. The... 
Via StockStory
1 Momentum Stock for Long-Term Investors and 2 Facing Challenges
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to new product launches, positive news, or even a dedicated social media... 
Via StockStory
Earnings Scheduled For August 5, 2025
 
Via Benzinga
Earnings Scheduled For May 6, 2025
 
Via Benzinga
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Royalty Pharma (NASDAQ:RPRX)
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Royalty Pharma (NASDAQ:RPRX) and its... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Why Are Supernus Pharmaceuticals (SUPN) Shares Soaring Today
Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) jumped 14.4% in the afternoon session after the company posted strong second-quarter earnings that beat expectations... 
Via StockStory
Supernus Pharmaceuticals (NASDAQ:SUPN) Beats Expectations in Strong Q2, Guides for Strong Full-Year Sales
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q2 CY2025 results topping the market’s revenue expectations, but sales fell by 1.7% year on year to $165.5 million. The... 
Via StockStory
Supernus Pharmaceuticals (SUPN) Reports Earnings Tomorrow: What To Expect
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be reporting results this Tuesday afternoon. Here’s what investors should know. 
Via StockStory
Why Supernus Pharmaceuticals (SUPN) Stock Is Up Today
Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) jumped 3.1% in the morning session after Cantor Fitzgerald upgraded the stock to Overweight from Neutral and raised its... 
Via StockStory
Topics Lawsuit
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Supernus Pharmaceuticals (NASDAQ:SUPN) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Why Supernus Pharmaceuticals (SUPN) Shares Are Falling Today
Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) fell 3.2% in the afternoon session after several negative developments weighed on the sector. Weakness in managed care... 
Via StockStory
Topics Artificial Intelligence Lawsuit
SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) - An Undervalued Stock With Strong Fundamentals
SUPERNUS PHARMACEUTICALS (NASDAQ:SUPN) is an undervalued stock with strong profitability, no debt, and steady growth—making it a potential pick for value investors. 
Via Chartmill
1 Stock Under $50 with Exciting Potential and 2 to Turn Down
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
Via StockStory
2 Cash-Heavy Stocks to Own for Decades and 1 to Approach with Caution
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow. 
Via StockStory
Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms
Analysts have also noted that the relatively low breakup fee may leave room for a competing offer, possibly from Biogen. 
Via Stocktwits
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News
 
Via Benzinga
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics
Under the terms of the deal, Supernus is looking to acquire Sage for a total consideration of $12 per share in cash. 
Via Stocktwits
Topics Government
Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal
Supernus to acquire Sage Therapeutics for $795 million, gaining Zurzuvae and aiming for $200 million in annual cost synergies by expanding its CNS portfolio. 
Via Benzinga
Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million
The deal expands Supernus Pharmaceuticals' presence in the nonpsychiatric space. 
Via Investor's Business Daily
Topics ETFs
3 Small-Cap Stocks Facing Headwinds
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
1 Cash-Producing Stock for Long-Term Investors and 2 to Keep Off Your Radar
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
3 Cash-Heavy Stocks in the Doghouse
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow. 
Via StockStory
3 Dawdling Stocks with Mounting Challenges
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
3 Stocks Under $50 That Concern Us
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
Via StockStory
Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 Sales Beat Estimates But Full-Year Sales Guidance Misses Expectations
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 4.3% year on year to $149.8 million. On the... 
Via StockStory
Topics Earnings
Uncovering Potential: Supernus Pharmaceuticals's Earnings Preview
 
Via Benzinga
Supernus Pharmaceuticals Earnings: What To Look For From SUPN
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be reporting earnings tomorrow after market close. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
3 Healthcare Stocks with Mounting Challenges
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.